Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29333715 | 0.94 | ADRA2A (0.42) | ADRA2AADRA1AALDH1A1MAPTBLM | |
| SCHEMBL12314639 | 0.94 | ADRA2A (0.42) | ADRA2AADRA1AALDH1A1MAPTBLM | |
| SCHEMBL813361 | 0.91 | ADRA2A (0.54) | ADRA2AADRA1AALDH1A1MAPTBLM | |
| SCHEMBL13635974 | 0.91 | ALDH1A1 (0.56) | ADRA2AADRA1AALDH1A1MAPTBLM | |
| Propene SCHEMBL12971206 | 0.90 | ADRA2A (0.39) | ADRA2AADRA1AALDH1A1MAPTBLM | |
| SCHEMBL15131901 | 0.87 | DGKA (0.50) | ADRA2AADRA1AALDH1A1MAPTBLM | |
| SCHEMBL14434076 | 0.87 | DGKA (0.55) | ADRA2AADRA1AALDH1A1MAPTBLM | |
| SCHEMBL14296732 | 0.87 | ADRA2A (0.43) | ADRA2AADRA1AALDH1A1MAPTBLM | |
| SCHEMBL11997756 | 0.87 | ALDH1A1 (0.47) | ADRA2AADRA1AALDH1A1MAPTBLM | |
| SCHEMBL14579714 | 0.86 | MAPT (0.46) | ALDH1A1MAPTTSHRLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113767097-B | Prodrugs of caspase inhibitors | 株式会社LG化学 | 2025-03-14 | — | — | CN | disclosed |
| EP-3994117-B1 | HYDROGENATION OF ESTERS TO ALCOHOLS IN THE PRESENCE OF A RU-PNN COMPLEX | BASF SE (DE) | 2024-07-03 | — | — | EP | disclosed |
| US-11911521-B2 | Antibacterial nanofiber | UNIVERSITY OF MANITOBA (CA) | 2024-02-27 | — | — | US | disclosed |
| US-11791459-B2 | Electrochemically active materials and methods of preparing the same | ENEVATE CORPORATION (US) | 2023-10-17 | — | — | US | disclosed |
| US-11767467-B2 | Photochromic compound and curable composition containing said photochromic compound | TOKUYAMA CORPORATION (JP) | 2023-09-26 | — | — | US | disclosed |
| US-20230280500-A1 | PHOTOCHROMIC COMPOUND, PHOTOCHROMIC CURABLE COMPOSITION, CURED BODY, LENS AND EYEGLASSES | TOKUYAMA CORPORATION (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230242809-A1 | PHOTOCHROMIC HYDROXYURETHANE COMPOUND | TOKUYAMA CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230242809-A1 | PHOTOCHROMIC HYDROXYURETHANE COMPOUND | TOKUYAMA CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| US-11708316-B2 | Hydrogenation of esters to alcohols in the presence of a Ru-PNN complex | BASF SE (DE) | 2023-07-25 | — | — | US | disclosed |
| US-11708316-B2 | Hydrogenation of esters to alcohols in the presence of a Ru-PNN complex | BASF SE (DE) | 2023-07-25 | — | — | US | disclosed |
| US-20110150837-A1 | Amphiphilic polymer functionalized by methionine | FLAMEL TECHNOLOGIES (FR) | 2011-06-23 | — | — | US | disclosed |
| US-20110082264-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | SEGETIS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110076423-A1 | CELLULOSE ACYLATE FILM, RETARDATION FILM, POLARIZER AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2011-03-31 | — | — | US | disclosed |
| WO-2009146202-A2 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | SEGETIS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090192113-A1 | Interfering RNA Duplex Having Blunt-Ends and 3`-Modifications | WEILER JAN | 2009-07-30 | — | — | US | disclosed |
| US-20090047270-A1 | ENZYMATIC ANTICANCER THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ENZON PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
| US-7301041-B2 | Bi-functional metallocenes, preparation process and use in the labeling or biological molecules | BIO MERIEUX (FR) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911521-B2 | Antibacterial nanofiber | AADAC, USP39, DLAT | ADRA2A 4741/4885ADRA1A 4761/4885ALDH1A1 3377/4885 |
| US-20090047270-A1 | ENZYMATIC ANTICANCER THERAPY | RNASE1, ADA, DCTD | ADRA2A 3322/4885ADRA1A 3332/4885ALDH1A1 140/4885 |
| US-20110150837-A1 | Amphiphilic polymer functionalized by methionine | MTR, LNPEP, METAP1 | ADRA2A 2376/4885ADRA1A 2046/4885ALDH1A1 3801/4885 |
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ADA, CDA, DCTD | ADRA2A 2035/4885ADRA1A 2051/4885ALDH1A1 105/4885 |
| US-20110082264-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | TKT, KHK, KYAT3 | ADRA2A 4577/4885ADRA1A 4582/4885ALDH1A1 2261/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | ADRA2A 1110/4885ADRA1A 1020/4885ALDH1A1 2303/4885 |
| US-11708316-B2 | Hydrogenation of esters to alcohols in the presence of a Ru-PNN complex | ADH1A, PNN, ADH1C | ADRA2A 1882/4885ADRA1A 986/4885ALDH1A1 103/4885 |
| US-20090192113-A1 | Interfering RNA Duplex Having Blunt-Ends and 3`-Modifications | NSUN3, NSUN2, RNGTT | ADRA2A 1910/4885ADRA1A 1534/4885ALDH1A1 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.